다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Journal of Korean medical science : JKMS, v.20 no.4 = no.104, 2005년, pp.598 - 602
Lee, Keun-Wook (Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.) , Yun, Tak (Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.) , Song, Eun Kee (Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.) , Na, Im il (Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.) , Shin, Hyunchoon (Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.) , Bang, Soo-Mee (Department of Internal Medicine, Gachon Medical School, Incheon, Korea.) , Lee, Jae Hoon (Department of Internal Medicine, Gachon Medical School, Incheon, Korea.) , Lee, Seung Tae (Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.) , Kim, Jee Hyun (Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.) , Yoon, Sung-Soo (Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.) , Lee, Jong Seok (Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea) , Park, Seonyang , Kim, Byoung Kook , Kim, Noe Kyeong
AI-Helper
Recent clinical trials showed that bortezomib, a novel proteasome inhibitor, had therapeutic activity in multiple myeloma. However, there was no data about the feasibility of bortezomib in Korean patients. We performed a pilot study of bortezomib in patients with relapsed or refractory myeloma (1.3 ...
1 The Korean Society of Hematology A statistical study of multiple myeloma in Korea Korean J Hematol 1995 30 345 361
2 Alexanian R Dimopoulos M The treatment of multiple myeloma N Engl J Med 1994 330 484 489 8289856
3 Belch A Shelley W Bergsagel D Wilson K Klimo P White D Willan A A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients Br J Cancer 1988 57 94 99 3279997
4 Myeloma Trialists' Collaborative Group Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials J Clin Oncol 1998 16 3832 3842 9850028
5 Boccadoro M Marmont F Tribalto M Avvisati G Andriani A Barbui T Cantonetti M Carotenuto M Comotti B Dammacco F Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients J Clin Oncol 1991 9 444 448 1999714
6 Vesole DH Barlogie B Jagannath S Cheson B Tricot G Alexanian R Crowley J High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants Blood 1994 84 950 956 7913845
7 Attal M Harousseau JL Facon T Guilhot F Doyen C Fuzibet JG Monconduit M Hulin C Caillot D Bouabdallah R Voillat L Sotto JJ Grosbois B Bataille R Single versus double autologous stem-cell transplantation for multiple myeloma N Engl J Med 2003 349 2495 2502 14695409
8 Attal M Harousseau JL Stoppa AM Sotto JJ Fuzibet JG Rossi JF Casassus P Maisonneuve H Facon T Ifrah N Payen C Bataille R A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome N Engl J Med 1996 335 91 97 8649495
9 Bang SM Cho EK Suh C Yoon SS Seong CM Cho KS Kang YG Park S Ahn MJ Park YS Oh D Kim HC Jung CW Kim S Lee JH High dose therapy followed by autologous peripheral blood stem cell transplantation as a first line treatment for multiple myeloma: a Korean Multicenter Study J Korean Med Sci 2003 18 673 678 14555819
10 Lee JL Kim SB Lee GW Ryu MH Kim E Kim S Kim WK Lee JS Kim SH Suh C The efficacy of high-dose melphalan with autologous peripheral blood stem cell transplantation in patients with multiple myeloma Yonsei Med J 2003 44 800 810 14584095
11 Singhal S Mehta J Desikan R Ayers D Roberson P Eddlemon P Munshi N Anaissie E Wilson C Dhodapkar M Zeddis J Barlogie B Antitumor activity of thalidomide in refractory multiple myeloma N Engl J Med 1999 341 1565 1571 10564685
12 Rajkumar SV Witzig TE A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma Cancer Treat Rev 2000 26 351 362 11006136
13 Juliusson G Celsing F Turesson I Lenhoff S Adriansson M Malm C Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma Br J Haematol 2000 109 89 96 10848786
14 Barlogie B Desikan R Eddlemon P Spencer T Zeldis J Munshi N Badros A Zangari M Anaissie E Epstein J Shaughnessy J Ayers D Spoon D Tricot G Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients Blood 2001 98 492 494 11435324
15 Kim DY Im SA Seong CM Lee SN Bang SM Lee JH Yoon SS Kim BK Park SY Ahn MJ Salvage therapy with thalidomide in patients with relapsed or refractory multiple myeloma Korean J Hematol 2002 37 259 264
16 Richardson PG Barlogie B Berenson J Singhal S Jagannath S Irwin D Rajkumar SV Srkalovic G Alsina M Alexanian R Siegel D Orlowski RZ Kuter D Limentani SA Lee S Hideshima T Esseltine DL Kauffman M Adams J Schenkein DP Anderson KC A phase 2 study of bortezomib in relapsed, refractory myeloma N Engl J Med 2003 348 2609 2617 12826635
17 Jagannath S Barlogie B Berenson J Siegel D Irwin D Richardson PG Niesvizky R Alexanian R Limentani SA Alsina M Adams J Kauffman M Esseltine DL Schenkein DP Anderson KC A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma Br J Haematol 2004 127 165 172 15461622
18 Blade J Samson D Reece D Apperley J Bjorkstrand B Gahrton G Gertz M Giralt S Jagannath S Vesole D Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant Br J Haematol 1998 102 1115 1123 9753033
19 Kisselev AF Goldberg AL Proteasome inhibitors: from research tools to drug candidates Chem Biol 2001 8 739 758 11514224
20 King RW Deshaies RJ Peters JM Kirschner MW How proteolysis drives the cell cycle Science 1996 274 1652 1659 8939846
21 Adams J Behnke M Chen S Cruickshank AA Dick LR Grenier L Klunder JM Ma YT Plamondon L Stein RL Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids Bioorg Med Chem Lett 1998 8 333 338 9871680
22 LeBlanc R Catley LP Hideshima T Lentzsch S Mitsiades CS Mitsiades N Neuberg D Goloubeva O Pien CS Adams J Gupta D Richardson PG Munshi NC Anderson KC Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model Cancer Res 2002 62 4996 5000 12208752
23 Hideshima T Richardson P Chauhan D Palombella VJ Elliott PJ Adams J Anderson KC The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells Cancer Res 2001 61 3071 3076 11306489
24 Mitsiades N Mitsiades CS Poulaki V Chauhan D Fanourakis G Gu X Bailey C Joseph M Libermann TA Treon SP Munshi NC Richardson PG Hideshima T Anderson KC Molecular sequelae of proteasome inhibition in human multiple myeloma cells Proc Natl Acad Sci USA 2002 99 14374 14379 12391322
25 Hideshima T Mitsiades C Akiyama M Hayashi T Chauhan D Richardson P Schlossman R Podar K Munshi NC Mitsiades N Anderson KC Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341 Blood 2003 101 1530 1534 12393500
26 Mitsiades CS Treon SP Mitsiades N Shima Y Richardson P Schlossman R Hideshima T Anderson KC TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications Blood 2001 98 795 804 11468181
27 Orlowski RZ Stinchcombe TE Mitchell BS Shea TC Baldwin AS Stahl S Adams J Esseltine DL Elliott PJ Pien CS Guerciolini R Anderson JK Depcik-Smith ND Bhagat R Lehman MJ Novick SC O'Connor OA Soignet SL Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies J Clin Oncol 2002 20 4420 4427 12431963
28 Bross PF Kane R Farrell AT Abraham S Benson K Brower ME Bradley S Gobburu JV Goheer A Lee SL Leighton J Liang CY Lostritto RT McGuinn WD Morse DE Rahman A Rosario LA Verbois SL Williams G Wang YC Pazdur R Approval summary for bortezomib for injection in the treatment of multiple myeloma Clin Cancer Res 2004 10 3954 3964 15217925
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.